We aim to influence policy developments so that researchers can be as effective as possible and health can be improved.
We work with a wide range of partners – including governments, research funders, learned societies, charities and commercial organisations – in the UK, Europe and globally.
UK and EU Policy
Head of UK and EU Policy
PA and Team Coordinator
EU and Public Affairs Manager
Brexit, public affairs, relationship management, EU health and research policy.
UK research investment, funding structures, Research Excellence Framework, What’s it Worth studies.
EU medical devices regulations, immigration, innovation policy, All-Party Parliamentary Group on Medical Research, parliamentary communications, diversity.
Global Policy Lead
Global Policy Lead
Interim Team Coordinator
access to medicines, emerging technologies.
global review of health research financing, vaccines.
Research Ethics and Governance Manager
research ethics and governance, UK Biobank Ethics and Governance Council, Global Forum on Bioethics in Research.
access to medicines, drug-resistant infections.
global review of health research financing.
We want the research we fund – like publications, data, software and materials – to be open and accessible, so it can have the greatest possible impact.
We're working with the UK government and others to achieve a Brexit settlement that allows research to thrive in the UK and Europe.
Patient data is hugely valuable for research. But the value of that data can only be unlocked if concerns about patient privacy are taken seriously.
Good research practice is one of the foundations of high-quality research.
Government investment plays an important part in supporting scientific excellence in the UK.
Research is an essential part of being ready for and responding to public health emergencies.
The recommendations set out in the review mark one of the first steps towards making sure that promising drugs, devices, diagnostics and digital products are adopted quickly across the NHS.
Gene editing allows scientists to change gene sequences by adding, replacing or removing sections of DNA.
The new European Data Protection Regulation was agreed in April 2016 and will take effect from May 2018.
The European Commission has published a proposal to update EU copyright law so that it applies equally across Europe and is fit for purpose in the 21st century.
Almost every major breakthrough in human and veterinary medicine has depended on the use of animals in the research, development or testing of new therapies.
Mitochondrial donation is an IVF technique that gives families affected by mitochondrial disease the chance of having healthy children.
The European Union is revising regulations governing the manufacture and sale of medical devices.
The Expert Advisory Group on Data Access promoted good working practices, consistent governance and transparent decision making for managing and using data from cohort studies.
A synthesis of the existing evidence on the EU-UK relationship on research and innovation, produced by the Royal Society.
A briefing on the economic benefits of musculoskeletal disease research in the UK.
Together with the Royal Society, we asked individuals and organisations from across the UK and EU for their recommendations about how future research and innovation partnerships should work after Brexit.
Briefings and responses
Migratory Advisory Committee
House of Commons Science and Technology Committee
House of Lords